Agents for preventing or ameliorating insulin resistance and/or obesity

Abstract

An object of the present invention is to provide a prophylactic or ameliorative agent for insulin resistance and/or obesity based on a new concept, and a screening method therefor. The present inventors found that GIP causes insulin resistance and obesity by a new mechanism, and obtained a new concept that a GIP function inhibitory compound exhibits the ameliorative effect of insulin resistance and anti-obesity effect, thereby completing the present invention. That is, the present invention is a prophylactic or ameliorative agent for insulin resistance and/or obesity, having a GIP function inhibitory compound as an active ingredient, and a screening method for a prophylactic or ameliorative agent for insulin resistance and/or obesity, characterized by selecting a GIP function inhibitory compound.

Dependencies are inferred from the claim text.